<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Prev Med</journal-id><journal-id journal-id-type="iso-abbrev">Int J Prev Med</journal-id><journal-id journal-id-type="publisher-id">IJPVM</journal-id><journal-title-group><journal-title>International Journal of Preventive Medicine</journal-title></journal-title-group><issn pub-type="ppub">2008-7802</issn><issn pub-type="epub">2008-8213</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24932388</article-id><article-id pub-id-type="pmc">4050677</article-id><article-id pub-id-type="publisher-id">IJPVM-5-569</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Reducing the Incidence of Chronic Lung Disease in Very Premature Infants with Aminophylline</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Armanian</surname><given-names>Amir-Mohammad</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Badiee</surname><given-names>Zohreh</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Afghari</surname><given-names>Raha</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Salehimehr</surname><given-names>Nima</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Hassanzade</surname><given-names>Akbar</given-names></name><xref ref-type="aff" rid="aff4">3</xref></contrib><contrib contrib-type="author"><name><surname>Sheikhzadeh</surname><given-names>Soghra</given-names></name><xref ref-type="aff" rid="aff5">4</xref></contrib><contrib contrib-type="author"><name><surname>Shariftehrani</surname><given-names>Maryam</given-names></name><xref ref-type="aff" rid="aff6">5</xref></contrib><contrib contrib-type="author"><name><surname>Rezvan</surname><given-names>Gohar</given-names></name><xref ref-type="aff" rid="aff7">6</xref></contrib></contrib-group><aff id="aff1">Department of Pediatrics, Division of Neonatology, Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff2"><label>1</label>Department of Pediatrics, Division of Neonatology, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff3"><label>2</label>Almahdi University, Isfahan, Iran</aff><aff id="aff4"><label>3</label>Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff5"><label>4</label>Department of Pediatrics, Division of Neonatology, Alzahra Hospital NICU, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff6"><label>5</label>Alzahra Hospital Neonatal Unit, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff7"><label>6</label>Shahid Beheshti Hospital NICU, Isfahan University of Medical Sciences, Isfahan, Iran</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Dr. Amir-Mohammad Armanian, No. 133, Shahid Ansari Alley, Saeb Street, Postal Code: 8184757851, Isfahan, Iran. E-mail: <email xlink:href="armanian@med.mui.ac.ir">armanian@med.mui.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>2014</year></pub-date><volume>5</volume><issue>5</issue><fpage>569</fpage><lpage>576</lpage><history><date date-type="received"><day>08</day><month>5</month><year>2013</year></date><date date-type="accepted"><day>14</day><month>1</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; International Journal of Preventive Medicine</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>The objective of this study is to assess the safety and preventative effects of aminophylline on the incidence of chronic lung disease (CLD) in very premature infants.</p></sec><sec id="st2"><title>Methods:</title><p>This was a long follow-up randomized clinical trial. The prophylactic effect of aminophylline on the incidence of CLD was investigated in very premature infants. The study group received aminophylline for the 1<sup>st</sup> 10 days of life and control infants received no aminophylline during the 1<sup>st</sup> 10 days of life.</p></sec><sec id="st3"><title>Results:</title><p>Fifty-two infants participated (26 aminophylline, 26 controls). Premature infants on aminophylline had clearly shorter oxygen dependency time than those in the control group. Median time of oxygen dependency was 3 (0-9.5) days and 14 (3-40.5) days in group A and C, respectively (<italic>P</italic>: 0.001). Incidence of CLD was significantly different between the two groups. Only two infants (8.7%) on aminophylline developed CLD, when compared to 11 infants (44.0%), who did not receive aminophylline (<italic>P</italic>: 0.006). No side-effects were reported in the neonates (<italic>P</italic>: 1).</p></sec><sec id="st4"><title>Conclusions:</title><p>This study supports the preventative effects of aminophylline on the incidence of CLD in very premature infants. In other words, the more premature the infants, the greater will be the preventative effect of aminophylline on the incidence of CLD.</p></sec></abstract><kwd-group><kwd>Aminophylline</kwd><kwd>chronic lung disease</kwd><kwd>preterm neonates</kwd><kwd>prevention</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Premature parturitions are those which happen at &#x0003c;37 weeks gestational (post-menstrual) age.[<xref rid="ref1" ref-type="bibr">1</xref>] Due to the greatly improved methods of treating premature babies, more premature babies survive, particularly, extremely immature neonates.[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref>] Furthermore improvements in neonatal management reduce the mortality and morbidity of surviving premature infants.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref4" ref-type="bibr">4</xref>] Similarly, enhancement in assisted ventilation strategies, antenatal corticosteroids usage and postnatal surfactant administration has resulted in improved outcomes for extremely premature infants.[<xref rid="ref5" ref-type="bibr">5</xref>] Many efforts have been made to reduce damage and invasive procedures; even studies have been carried out to improve management and harm reduction with measurements of bilirubin through the skin (without phlebotomy).[<xref rid="ref6" ref-type="bibr">6</xref>]</p><p>Occurrence of premature birth continues to rise; for example, in the USA the premature parturition rate is 12-13%.[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref>] Chronic lung disease (CLD) or bronchopulmonary dysplasia (BPD) happens in premature neonates with respiratory distress syndrome (RDS) who require respiratory support in the 1<sup>st</sup> days after birth.[<xref rid="ref2" ref-type="bibr">2</xref>] However, as a result of the improved survival of extremely immature neonates the importance of CLD in the surviving neonatal populations increased.[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref10" ref-type="bibr">10</xref>]</p><p>Aside from prematurity, factors such as assisted ventilation methods/oxygen therapy, intrauterine/postnatal infections, patent ductus arteriosus (PDA) and genetic basis is added into its multi-factorial and complex pathogenesis.[<xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref>] These factors usually are interrelated to lung inflammation and an arrest of pulmonary development.[<xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref>]</p><p>It seems that reducing the incidence of CLD will need a comprehensive multipurpose approach focusing on various aspects of the path that leads to CLD.[<xref rid="ref11" ref-type="bibr">11</xref>]</p><p>Prematurity is the main risk factor in the development of CLD.[<xref rid="ref17" ref-type="bibr">17</xref><xref rid="ref18" ref-type="bibr">18</xref>] Langston <italic>et al</italic>. found that the saccular stage of lung development occurs between 23 and 32 weeks of gestation.[<xref rid="ref19" ref-type="bibr">19</xref>] At this stage, due to poor lung-supporting structures, underdeveloped compliance, incompleted antioxidant system, fluid accumulation and surfactant deficiency, the lung seems to be most at risk to injury. Therefore, a very high risk of lung damage exists if birth takes place within this stage of lung development.[<xref rid="ref19" ref-type="bibr">19</xref>] Then incidence of CLD in infants with RDS increases with a decrease of gestational age.[<xref rid="ref1" ref-type="bibr">1</xref>] Accordingly the various incidences of CLD were found in different studies; it is found in 30% of infants with birth weight &#x0003c;1000 g,[<xref rid="ref20" ref-type="bibr">20</xref>] 23% of infants &#x0003c;1500 g in a US study[<xref rid="ref21" ref-type="bibr">21</xref>] and 26% of infants in a Canadian study.[<xref rid="ref22" ref-type="bibr">22</xref>] Incidences of CLD may increase 2-3 times for each week of reduction in gestation.[<xref rid="ref23" ref-type="bibr">23</xref>] Currently, it is estimated that 97% of CLD cases occur among preterm infants with birth weights of &#x0003c;1250 g.[<xref rid="ref24" ref-type="bibr">24</xref>] Furthermore, growth retardation may have a considerable result on the susceptibility to lung damage.[<xref rid="ref25" ref-type="bibr">25</xref><xref rid="ref26" ref-type="bibr">26</xref>]</p><p>CLD, usually described as neonates being oxygen-dependent for at least 28 days after birth,[<xref rid="ref21" ref-type="bibr">21</xref>] is a common unfavorable outcome of immature birth.[<xref rid="ref27" ref-type="bibr">27</xref>]</p><p>Greenough and Ahmed proposed that &#x0201c;in the past, CLD/BPD developed after severe respiratory failure, usually associated by the PDA, pulmonary interstitial emphysema and/or infection, necessitating high-pressure ventilation and supplementary oxygen concentrations but new BPD, occurs in extremely premature infants who initially had minimal or even no signs of lung disease.&#x0201d;[<xref rid="ref27" ref-type="bibr">27</xref><xref rid="ref28" ref-type="bibr">28</xref>]</p><p>CLD results in serious morbidity despite the decline in mortality rates among VLBW neonates.[<xref rid="ref3" ref-type="bibr">3</xref>] CLD in premature neonates is presently a significant cause of mortality and long-term morbidity, such as recurrent pneumonia, growth retardation, decreased pulmonary function and poorer neurodevelopmental outcome.[<xref rid="ref21" ref-type="bibr">21</xref><xref rid="ref29" ref-type="bibr">29</xref><xref rid="ref30" ref-type="bibr">30</xref><xref rid="ref31" ref-type="bibr">31</xref>]</p><p>Based on what was described above, any attempt to reduce the incidence of CLD must be considered as an important and valuable work.[<xref rid="ref27" ref-type="bibr">27</xref>] Surely prevention of premature birth is the best way to reduce the incidence of CLD. Nevertheless, the preventative effectiveness of different approaches have been investigated.[<xref rid="ref27" ref-type="bibr">27</xref>]</p><p>Prenatal administration of corticosteroids, thyroid-releasing hormone and antioxidants has not been demonstrated to reduce BPD in clinical randomized trials.[<xref rid="ref32" ref-type="bibr">32</xref><xref rid="ref33" ref-type="bibr">33</xref><xref rid="ref34" ref-type="bibr">34</xref>] Roberts and Dalziel analyzed the results of 21 randomized controlled trials (RCTs), in which Corticosteroids were given antenatally. They found reductions in incidence of RDS, intraventricular hemorrhage, necrotizing enterocolitis and death, however, no reduction in the incidence of CLD were reported.[<xref rid="ref32" ref-type="bibr">32</xref>]</p><p>Furthermore, effectiveness of different postnatal approaches have been investigated such as assisted ventilation strategies modifications, administration of cromolyn sodium, thyroxine, antioxidants, macrolides, corticosteroids, inositol, surfactant, vitamin A, methylxanthines and estradiol/progesterone replacement.[<xref rid="ref27" ref-type="bibr">27</xref>]</p><p>Schmidt <italic>et al</italic>. in a large RCT found that caffeine has a significant effect in reduction of BPD. Also, caffeine was associated with a reduction in cerebral palsy.[<xref rid="ref35" ref-type="bibr">35</xref><xref rid="ref36" ref-type="bibr">36</xref>]</p><p>Given the importance of the prevention of CLD in preterm neonates, the researcher(s) decided to study the prophylactic effects of aminophylline on the incidence of CLD in high risk premature neonates (preterm neonate with a weight below 1200 g).</p></sec><sec sec-type="methods" id="sec1-2"><title>METHODS</title><sec id="sec2-1"><title>Study design and participants</title><p>The present study was a long follow-up randomized clinical trial (RCT). Neonates admitted to the neonatal intensive care unit at Alzahra and Shahid Beheshti Hospitals in Isfahan-Iran, between March 2012 and April 2013 were included in this study. The prophylactic effect of aminophylline on the incidence of CLD was investigated in two groups of aminophylline (group A) and control (group C).</p><p>Inclusion criteria were infants being born premature and at-birth weight of equal and lower than 1200 g. Infants who had major congenital anomalies, asphyxia, occurrence of apnea and need for mechanical ventilation in the first 24 h of birth, congenital cyanotic heart disease, small for gestational age-intrauterine growth and sepsis in the 1<sup>st</sup> 10 days of birth were excluded. The infants in the study were randomly assigned to aminophylline (group A) and no aminophylline (group C), as described below. In order to select the neonates, randomly, those with an even digit at the end of their file numbers were placed in group A and neonates with their file numbers ending in an odd digit were assigned to group C.</p></sec><sec id="sec2-2"><title>Experimental procedure</title><p>In the aminophylline group (A), after considering the inclusion and exclusion criteria for the premature neonate with a weight equal and lower than 1200 g, 5 mg/kg of aminophylline, as a loading dose, was begun (parenteral) then each 8 h, 1/5 mg/kg, as a maintenance dose, was administered for the 1<sup>st</sup> 10 days of life.</p><p>However, in the control group (C), after considering the inclusion and exclusion criteria for the premature neonate with a weight equal and lower than 1200 g, no aminophylline was given in 1<sup>st</sup> 10 days of life.</p><p>The primary and secondary outcomes of the study in both groups were the duration of dependency on oxygen and the effect of preventative aminophylline on incidence of CLD respectively, with a long follow-up. Decisions regarding CLD were made uniformly in both groups. In short, Neonates were considered as having CLD/BPD if they had been oxygen dependent for at least 28 days after birth and the severity of CLD was judged according to the <xref ref-type="table" rid="T1">Table 1</xref>.[<xref rid="ref21" ref-type="bibr">21</xref>] Aminophylline side-effects (tachycardia, hypertension) and also mortality for each neonate were recorded daily as other secondary outcomes.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Definition of bronchopulmonary dysplasia: Diagnostic criteria</p></caption><graphic xlink:href="IJPVM-5-569-g001"/></table-wrap><p>Written informed consents were obtained from parents before the study, with approval of the protocol by the ethical committee of our university.</p><p>This paper is derived from a residency thesis No. 391323 in Isfahan University of Medical Sciences. Our clinical trial registration ID in Iranian Registry of Clinical Trials (IRCT) is IRCT2013052610026N1.</p><p>The results were compared using the Chi-square, independent <italic>t</italic>-test and Mann-Whitney and Fisher's exact test. The data was analyzed with Statistical Package for the Social Sciences (SPSS) ver. 20.0 (SPSS Inc., Chicago, IL, USA).</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>In our study, 52 neonates were randomized and completed the study [<xref ref-type="fig" rid="F1">Figure 1</xref>] and the results were analyzed with the intention to promote treatment and health of premature neonates. Demographic characteristics were similar between the two groups [<xref ref-type="table" rid="T2">Table 2</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>CONSORT diagram showing the flow of samples through each stage of study</p></caption><graphic xlink:href="IJPVM-5-569-g002"/></fig><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Characteristics of study infants</p></caption><graphic xlink:href="IJPVM-5-569-g003"/></table-wrap><p>The primary outcome was clearly different between the two groups. Infants who had been placed in the aminophylline group (group A) had clearly shorter oxygen dependency time than the infants in the control group (group C). Median time of oxygen dependency in group A was 3 (0-9.5) days and in group C 14 (3-40.5) days [<italic>P</italic>: 0.001; <xref ref-type="table" rid="T3">Table 3</xref>]. Duration of oxygen dependency ranged from 0-30 days to 0-82 days in group A and C, respectively.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Primary and secondary outcomes in our study</p></caption><graphic xlink:href="IJPVM-5-569-g004"/></table-wrap><p>Average gestational ages in group A were 29.89 &#x000b1; 1.93 and in group C, 28.59 &#x000b1; 2.06. Average birth weights in group A were 1071.54 &#x000b1; 117.56 g and in group C, 1007.69 &#x000b1; 134.02, which means average gestational ages and birth weights were similar between the two groups [<italic>P</italic>: 0.10, <italic>P</italic>: 0.07, respectively; <xref ref-type="table" rid="T2">Table 2</xref>]. No side-effects were reported in neonates in both groups (<italic>P</italic>: 1). One and three neonates died in group C and A respectively [<italic>P</italic>: 0.31; <xref ref-type="table" rid="T3">Table 3</xref>].</p><p>Incidence of CLD was significantly different between the two groups. Only two infants (8.7%), who had been placed in aminophylline group developed CLD, when compared to 11 infants (44.0%) who had not received aminophylline [<italic>P</italic>: 0.006; <xref ref-type="table" rid="T3">Table 3</xref>].</p><p>Birth weights of those infants who developed CLD in group C (not receiving aminophylline) ranged from 600 to 1150 g (average birth weights: 941.81 g) and gestational ages ranged from 25 to 30 weeks (average gestational ages: 27.18 weeks). Except one neonate who developed moderate CLD in group C, others developed mild CLD at 36 weeks&#x02019; postmenstrual age (PMA) in both groups. Characteristics of infants who developed CLD are shown in <xref ref-type="table" rid="T4">Table 4</xref>.</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Characteristics of neonates with CLD</p></caption><graphic xlink:href="IJPVM-5-569-g005"/></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>In this study, prophylactic aminophylline was effective in the reduction of CLD incidence in very premature neonates (preterm neonate with a weight below 1200 g).</p><p>The effectiveness of different postnatal drugs in preventing the occurrence of CLD have been investigated in some clinical trials. In a review article Greenough and Ahmed[<xref rid="ref27" ref-type="bibr">27</xref>] proposed that although using surfactant in infants with RDS has been associated with many benefits, but it had no effect on the incidence of CLD &#x0201c;possibly because of the increased survival of very prematurely born infants following surfactant administration.&#x0201d;</p><p>Howlett and Ohlsson, Ng and Ohlsson showed that inositol and cromolyn sodium did not have any effect on reduction of CLD.[<xref rid="ref37" ref-type="bibr">37</xref><xref rid="ref38" ref-type="bibr">38</xref>] Also postnatal administration of antioxidants such as glutathionine, N-acetyl cysteine, melatonin, etc., had no association with developing CLD.[<xref rid="ref39" ref-type="bibr">39</xref><xref rid="ref40" ref-type="bibr">40</xref><xref rid="ref41" ref-type="bibr">41</xref>] A study by Darlow and Graham found that postnatal vitamin A has a significant reduction effect in developing CLD at 36 weeks&#x02019; PMA in extremely low birth weight infants.[<xref rid="ref42" ref-type="bibr">42</xref>]</p><p>Some studies have investigated the effect of methylxanthines on CLD incidence. Lauterbach <italic>et al</italic>. tried pentoxifylline administration in VLBW neonates if they needed supplementary oxygen on the fourth postnatal day. They observed a significant reduction in occurrence of CLD compared with a placebo group (odds ratio [OR] 0.32, 95% confidence interval [CI] 0.11-0.94).[<xref rid="ref43" ref-type="bibr">43</xref>] In addition, in a large study of Schmidt <italic>et al</italic>., caffeine usage caused a significant reduction in CLD development (OR 0.63, 95% CI 0.52-0.78). In that study they investigated neonates who needed respiratory stimulant to prevent apnea or to assist extubation throughout the 1<sup>st</sup> 10 postnatal days.[<xref rid="ref35" ref-type="bibr">35</xref><xref rid="ref36" ref-type="bibr">36</xref>] In the present study, incidence of CLD was significantly lower in the aminophylline receiving group than the control group, possibly due to improvement in respiration (with increasing diaphragmatic contractility) and the mild diuresis effect of aminophylline.</p><p>Replacement of estradiol/progesterone or thyroxine by some researchers failed to reduce the prevalence of CLD.[<xref rid="ref44" ref-type="bibr">44</xref><xref rid="ref45" ref-type="bibr">45</xref>] Schreiber <italic>et al</italic>. showed that the Nitric oxide administration in routine dose (starting at 10 ppm) reduced death or CLD/BPD and also intracranial hemorrhage, significantly.[<xref rid="ref46" ref-type="bibr">46</xref>]</p><p>This study was designed to investigate preventive effects of aminophylline on the reduction of CLD development in the higher risk neonates. The results revealed that, among extremely premature infants, preventative effects of aminophylline on CLD become apparent. Further investigation should, of course, be carried out to corroborate the findings of the present study.</p><p>The major limitation of this study could be the rather small number of the infants included (52 premature neonates), even though the results clearly indicated a statistically significant difference between the experimental and control groups. On the other hand, the direct supervision of study by a neonatologist may be considered as the major strength of the study.</p></sec><sec sec-type="conclusion" id="sec1-5"><title>CONCLUSIONS</title><p>Apparently, with the study implemented among extremely premature infants, preventative effects of aminophylline on CLD become apparent. In fact, it seems the more premature the infants, the greater will be the preventative effect of aminophylline on the incidence of CLD.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> This paper is derived from a residency thesis No. 391323 in Isfahan University of Medical Sciences.</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>Z</given-names></name><name><surname>Schmidt</surname><given-names>P</given-names></name><name><surname>Dodd</surname><given-names>J</given-names></name><name><surname>Jeppesen</surname><given-names>DL</given-names></name></person-group><article-title>Bronchopulmonary dysplasia: A review</article-title><source>Arch Gynecol Obstet</source><year>2013</year><volume>288</volume><fpage>325</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">23420126</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>V</given-names></name><name><surname>Tan</surname><given-names>JB</given-names></name></person-group><article-title>Chronic lung disease in preterm neonates</article-title><source>World J Pediatr</source><year>2007</year><volume>3</volume><fpage>170</fpage><lpage>86</lpage></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldenberg</surname><given-names>RL</given-names></name><name><surname>Jobe</surname><given-names>AH</given-names></name></person-group><article-title>Prospects for research in reproductive health and birth outcomes</article-title><source>JAMA</source><year>2001</year><volume>285</volume><fpage>633</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11176872</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeitlin</surname><given-names>J</given-names></name><name><surname>Ancel</surname><given-names>PY</given-names></name><name><surname>Delmas</surname><given-names>D</given-names></name><name><surname>Br&#x000e9;art</surname><given-names>G</given-names></name><name><surname>Papiernik</surname><given-names>E</given-names></name></person-group><collab>EPIPAGE and MOSAIC Ile-de-France Groups</collab><article-title>Changes in care and outcome of very preterm babies in the Parisian region between 1998 and 2003</article-title><source>Arch Dis Child Fetal Neonatal Ed</source><year>2010</year><volume>95</volume><fpage>F188</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">19395393</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iams</surname><given-names>JD</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Culhane</surname><given-names>JF</given-names></name><name><surname>Goldenberg</surname><given-names>RL</given-names></name></person-group><article-title>Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth</article-title><source>Lancet</source><year>2008</year><volume>371</volume><fpage>164</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">18191687</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badiee</surname><given-names>Z</given-names></name><name><surname>Mohammadizadeh</surname><given-names>M</given-names></name><name><surname>Shamee</surname><given-names>M</given-names></name></person-group><article-title>Diagnostic usefulness of transcutaneous bilirubinometry in very preterm newborns</article-title><source>Int J Prev Med</source><year>2012</year><volume>3</volume><fpage>262</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">22624082</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="webpage"><article-title>Institute of Medicine of the National Academies. Preterm birth: Causes, consequences, and prevention</article-title><year>2006</year><date-in-citation>Last accessed on 2010 Jun 15</date-in-citation><comment>Available from: <uri xlink:type="simple" xlink:href="http://www.iom.edu/Reports/2006/Preterm-Birth-Causes-Consequences-and-Prevention.aspx">http://www.iom.edu/Reports/2006/Preterm-Birth-Causes-Consequences-and-Prevention.aspx</uri></comment></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldenberg</surname><given-names>RL</given-names></name><name><surname>Culhane</surname><given-names>JF</given-names></name><name><surname>Iams</surname><given-names>JD</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name></person-group><article-title>Epidemiology and causes of preterm birth</article-title><source>Lancet</source><year>2008</year><volume>371</volume><fpage>75</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">18177778</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doyle</surname><given-names>LW</given-names></name></person-group><collab>Victorian Infant Collaborative Study Group</collab><article-title>Evaluation of neonatal intensive care for extremely low birth weight infants in Victoria over two decades: I. Effectiveness</article-title><source>Pediatrics</source><year>2004</year><volume>113</volume><fpage>505</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">14993541</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>RA</given-names></name><name><surname>Lindstrom</surname><given-names>DP</given-names></name><name><surname>Cotton</surname><given-names>RB</given-names></name></person-group><article-title>Improved survival accounts for most, but not all, of the increase in bronchopulmonary dysplasia</article-title><source>Pediatrics</source><year>1992</year><volume>90</volume><fpage>663</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1408535</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>LY</given-names></name></person-group><article-title>Bronchopulmonary dysplasia and chronic lung disease of infancy: Strategies for prevention and management</article-title><source>Ann Acad Med Singapore</source><year>2002</year><volume>31</volume><fpage>119</fpage><lpage>30</lpage><comment>131</comment><pub-id pub-id-type="pmid">11885487</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Brodovich</surname><given-names>HM</given-names></name><name><surname>Mellins</surname><given-names>RB</given-names></name></person-group><article-title>Bronchopulmonary dysplasia. Unresolved neonatal acute lung injury</article-title><source>Am Rev Respir Dis</source><year>1985</year><volume>132</volume><fpage>694</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">3898946</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrell</surname><given-names>PA</given-names></name><name><surname>Fiascone</surname><given-names>JM</given-names></name></person-group><article-title>Bronchopulmonary dysplasia in the 1990s: A review for the pediatrician</article-title><source>Curr Probl Pediatr</source><year>1997</year><volume>27</volume><fpage>129</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">9145287</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jobe</surname><given-names>AH</given-names></name><name><surname>Ikegami</surname><given-names>M</given-names></name></person-group><article-title>Antenatal infection/inflammation and postnatal lung maturation and injury</article-title><source>Respir Res</source><year>2001</year><volume>2</volume><fpage>27</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">11686862</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jobe</surname><given-names>AJ</given-names></name></person-group><article-title>The new BPD: An arrest of lung development</article-title><source>Pediatr Res</source><year>1999</year><volume>46</volume><fpage>641</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">10590017</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bancalari</surname><given-names>E</given-names></name><name><surname>Claure</surname><given-names>N</given-names></name><name><surname>Sosenko</surname><given-names>IR</given-names></name></person-group><article-title>Bronchopulmonary dysplasia: Changes in pathogenesis, epidemiology and definition</article-title><source>Semin Neonatol</source><year>2003</year><volume>8</volume><fpage>63</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">12667831</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farstad</surname><given-names>T</given-names></name><name><surname>Bratlid</surname><given-names>D</given-names></name><name><surname>Medb&#x000f8;</surname><given-names>S</given-names></name><name><surname>Markestad</surname><given-names>T</given-names></name></person-group><collab>Norwegian Extreme Prematurity Study Group</collab><article-title>Bronchopulmonary dysplasia-prevalence, severity and predictive factors in a national cohort of extremely premature infants</article-title><source>Acta Paediatr</source><year>2011</year><volume>100</volume><fpage>53</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">20653607</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Lodha</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>PS</given-names></name><name><surname>Sankaran</surname><given-names>K</given-names></name><name><surname>Seshia</surname><given-names>MM</given-names></name><name><surname>Yee</surname><given-names>W</given-names></name><etal/></person-group><article-title>Neonatal outcomes of small for gestational age preterm infants in Canada</article-title><source>Am J Perinatol</source><year>2012</year><volume>29</volume><fpage>87</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">22131047</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langston</surname><given-names>C</given-names></name><name><surname>Kida</surname><given-names>K</given-names></name><name><surname>Reed</surname><given-names>M</given-names></name><name><surname>Thurlbeck</surname><given-names>WM</given-names></name></person-group><article-title>Human lung growth in late gestation and in the neonate</article-title><source>Am Rev Respir Dis</source><year>1984</year><volume>129</volume><fpage>607</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">6538770</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jobe</surname><given-names>AH</given-names></name><name><surname>Bancalari</surname><given-names>E</given-names></name></person-group><article-title>Bronchopulmonary dysplasia</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>163</volume><fpage>1723</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11401896</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemons</surname><given-names>JA</given-names></name><name><surname>Bauer</surname><given-names>CR</given-names></name><name><surname>Oh</surname><given-names>W</given-names></name><name><surname>Korones</surname><given-names>SB</given-names></name><name><surname>Papile</surname><given-names>LA</given-names></name><name><surname>Stoll</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network</article-title><source>Pediatrics</source><year>2001</year><volume>107</volume><fpage>E1</fpage><pub-id pub-id-type="pmid">11134465</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SK</given-names></name><name><surname>McMillan</surname><given-names>DD</given-names></name><name><surname>Ohlsson</surname><given-names>A</given-names></name><name><surname>Pendray</surname><given-names>M</given-names></name><name><surname>Synnes</surname><given-names>A</given-names></name><name><surname>Whyte</surname><given-names>R</given-names></name><etal/></person-group><article-title>Variations in practice and outcomes in the Canadian NICU network: 1996-1997</article-title><source>Pediatrics</source><year>2000</year><volume>106</volume><fpage>1070</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11061777</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palta</surname><given-names>M</given-names></name><name><surname>Sadek</surname><given-names>M</given-names></name><name><surname>Barnet</surname><given-names>JH</given-names></name><name><surname>Evans</surname><given-names>M</given-names></name><name><surname>Weinstein</surname><given-names>MR</given-names></name><name><surname>McGuinness</surname><given-names>G</given-names></name><etal/></person-group><article-title>Evaluation of criteria for chronic lung disease in surviving very low birth weight infants. Newborn Lung Project</article-title><source>J Pediatr</source><year>1998</year><volume>132</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">9470001</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>MC</given-names></name><name><surname>Szefler</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>J</given-names></name><name><surname>Allen</surname><given-names>M</given-names></name><name><surname>Van Marter</surname><given-names>L</given-names></name><name><surname>Abman</surname><given-names>S</given-names></name><etal/></person-group><article-title>Summary proceedings from the bronchopulmonary dysplasia group</article-title><source>Pediatrics</source><year>2006</year><volume>117</volume><fpage>S52</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16777823</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bose</surname><given-names>C</given-names></name><name><surname>Van Marter</surname><given-names>LJ</given-names></name><name><surname>Laughon</surname><given-names>M</given-names></name><name><surname>O&#x02019;Shea</surname><given-names>TM</given-names></name><name><surname>Allred</surname><given-names>EN</given-names></name><name><surname>Karna</surname><given-names>P</given-names></name><etal/></person-group><article-title>Fetal growth restriction and chronic lung disease among infants born before the 28 th week of gestation</article-title><source>Pediatrics</source><year>2009</year><volume>124</volume><fpage>e450</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19706590</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grisaru-Granovsky</surname><given-names>S</given-names></name><name><surname>Reichman</surname><given-names>B</given-names></name><name><surname>Lerner-Geva</surname><given-names>L</given-names></name><name><surname>Boyko</surname><given-names>V</given-names></name><name><surname>Hammerman</surname><given-names>C</given-names></name><name><surname>Samueloff</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mortality and morbidity in preterm small-for-gestational-age infants: A population-based study</article-title><source>Am J Obstet Gynecol</source><year>2012</year><volume>206</volume><fpage>150.e1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21982023</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenough</surname><given-names>A</given-names></name><name><surname>Ahmed</surname><given-names>N</given-names></name></person-group><article-title>Perinatal prevention of bronchopulmonary dysplasia</article-title><source>J Perinat Med</source><year>2013</year><volume>41</volume><fpage>119</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">23096098</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojas</surname><given-names>MA</given-names></name><name><surname>Gonzalez</surname><given-names>A</given-names></name><name><surname>Bancalari</surname><given-names>E</given-names></name><name><surname>Claure</surname><given-names>N</given-names></name><name><surname>Poole</surname><given-names>C</given-names></name><name><surname>Silva-Neto</surname><given-names>G</given-names></name></person-group><article-title>Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease</article-title><source>J Pediatr</source><year>1995</year><volume>126</volume><fpage>605</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">7699543</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauve</surname><given-names>RS</given-names></name><name><surname>Singhal</surname><given-names>N</given-names></name></person-group><article-title>Long-term morbidity of infants with bronchopulmonary dysplasia</article-title><source>Pediatrics</source><year>1985</year><volume>76</volume><fpage>725</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">4058982</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhutani</surname><given-names>VK</given-names></name><name><surname>Abbasi</surname><given-names>S</given-names></name></person-group><article-title>Long-term pulmonary consequences in survivors with bronchopulmonary dysplasia</article-title><source>Clin Perinatol</source><year>1992</year><volume>19</volume><fpage>649</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">1526076</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bregman</surname><given-names>J</given-names></name><name><surname>Farrell</surname><given-names>EE</given-names></name></person-group><article-title>Neurodevelopmental outcome in infants with bronchopulmonary dysplasia</article-title><source>Clin Perinatol</source><year>1992</year><volume>19</volume><fpage>673</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">1382004</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>D</given-names></name><name><surname>Dalziel</surname><given-names>S</given-names></name></person-group><article-title>Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth</article-title><source>Cochrane Database Syst Rev</source><year>2006</year><volume>3</volume><fpage>CD004454</fpage><pub-id pub-id-type="pmid">16856047</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crowther</surname><given-names>CA</given-names></name><name><surname>Alfirevic</surname><given-names>Z</given-names></name><name><surname>Haslam</surname><given-names>RR</given-names></name></person-group><article-title>Thyrotropin-releasing hormone added to corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease</article-title><source>Cochrane Database Syst Rev</source><year>2004</year><volume>3</volume><fpage>CD000019</fpage><pub-id pub-id-type="pmid">15106139</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenough</surname><given-names>A</given-names></name><name><surname>Shaheen</surname><given-names>SO</given-names></name><name><surname>Shennan</surname><given-names>A</given-names></name><name><surname>Seed</surname><given-names>PT</given-names></name><name><surname>Poston</surname><given-names>L</given-names></name></person-group><article-title>Respiratory outcomes in early childhood following antenatal vitamin C and E supplementation</article-title><source>Thorax</source><year>2010</year><volume>65</volume><fpage>998</fpage><lpage>1003</lpage><pub-id pub-id-type="pmid">20889523</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>B</given-names></name><name><surname>Roberts</surname><given-names>RS</given-names></name><name><surname>Davis</surname><given-names>P</given-names></name><name><surname>Doyle</surname><given-names>LW</given-names></name><name><surname>Barrington</surname><given-names>KJ</given-names></name><name><surname>Ohlsson</surname><given-names>A</given-names></name><etal/></person-group><article-title>Long-term effects of caffeine therapy for apnea of prematurity</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>1893</fpage><lpage>902</lpage><pub-id pub-id-type="pmid">17989382</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>B</given-names></name><name><surname>Roberts</surname><given-names>RS</given-names></name><name><surname>Davis</surname><given-names>P</given-names></name><name><surname>Doyle</surname><given-names>LW</given-names></name><name><surname>Barrington</surname><given-names>KJ</given-names></name><name><surname>Ohlsson</surname><given-names>A</given-names></name><etal/></person-group><article-title>Caffeine therapy for apnea of prematurity</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><fpage>2112</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">16707748</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howlett</surname><given-names>A</given-names></name><name><surname>Ohlsson</surname><given-names>A</given-names></name></person-group><article-title>Inositol for respiratory distress syndrome in preterm infants</article-title><source>Cochrane Database Syst Rev</source><year>2003</year><volume>4</volume><fpage>CD000366</fpage><pub-id pub-id-type="pmid">14583919</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>GY</given-names></name><name><surname>Ohlsson</surname><given-names>A</given-names></name></person-group><article-title>Cromolyn sodium for the prevention of chronic lung disease in preterm infants</article-title><source>Cochrane Database Syst Rev</source><year>2001</year><volume>2</volume><fpage>CD003059</fpage><pub-id pub-id-type="pmid">11406065</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Madsen</surname><given-names>DC</given-names></name><name><surname>Auld</surname><given-names>PA</given-names></name><name><surname>Frayer</surname><given-names>WW</given-names></name><name><surname>Schwartz</surname><given-names>MK</given-names></name><name><surname>Meister</surname><given-names>A</given-names></name><etal/></person-group><article-title>L-2-oxothiazolidine-4-carboxylate, a cysteine precursor, stimulates growth and normalizes tissue glutathione concentrations in rats fed a sulfur amino acid-deficient diet</article-title><source>J Nutr</source><year>1995</year><volume>125</volume><fpage>851</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7722686</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandberg</surname><given-names>K</given-names></name><name><surname>Fellman</surname><given-names>V</given-names></name><name><surname>Stigson</surname><given-names>L</given-names></name><name><surname>Thiringer</surname><given-names>K</given-names></name><name><surname>Hjalmarson</surname><given-names>O</given-names></name></person-group><article-title>N-acetylcysteine administration during the first week of life does not improve lung function in extremely low birth weight infants</article-title><source>Biol Neonate</source><year>2004</year><volume>86</volume><fpage>275</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15297790</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gitto</surname><given-names>E</given-names></name><name><surname>Reiter</surname><given-names>RJ</given-names></name><name><surname>Sabatino</surname><given-names>G</given-names></name><name><surname>Buonocore</surname><given-names>G</given-names></name><name><surname>Romeo</surname><given-names>C</given-names></name><name><surname>Gitto</surname><given-names>P</given-names></name><etal/></person-group><article-title>Correlation among cytokines, bronchopulmonary dysplasia and modality of ventilation in preterm newborns: Improvement with melatonin treatment</article-title><source>J Pineal Res</source><year>2005</year><volume>39</volume><fpage>287</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">16150110</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darlow</surname><given-names>BA</given-names></name><name><surname>Graham</surname><given-names>PJ</given-names></name></person-group><article-title>Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants</article-title><source>Cochrane Database Syst Rev</source><year>2007</year><volume>4</volume><fpage>CD000501</fpage><pub-id pub-id-type="pmid">17943744</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauterbach</surname><given-names>R</given-names></name><name><surname>Szymura-Oleksiak</surname><given-names>J</given-names></name><name><surname>Pawlik</surname><given-names>D</given-names></name><name><surname>Warcho&#x00142;</surname><given-names>J</given-names></name><name><surname>Lisowska-Miszczyk</surname><given-names>I</given-names></name><name><surname>Rytlewski</surname><given-names>K</given-names></name></person-group><article-title>Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in very low birth weight infants: A pilot clinical study</article-title><source>J Matern Fetal Neonatal Med</source><year>2006</year><volume>19</volume><fpage>433</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16923699</pub-id></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osborn</surname><given-names>DA</given-names></name><name><surname>Hunt</surname><given-names>RW</given-names></name></person-group><article-title>Postnatal thyroid hormones for respiratory distress syndrome in preterm infants</article-title><source>Cochrane Database Syst Rev</source><year>2007</year><volume>1</volume><fpage>CD005946</fpage><pub-id pub-id-type="pmid">17253569</pub-id></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trotter</surname><given-names>A</given-names></name><name><surname>Maier</surname><given-names>L</given-names></name><name><surname>Kron</surname><given-names>M</given-names></name><name><surname>Pohlandt</surname><given-names>F</given-names></name></person-group><article-title>Effect of oestradiol and progesterone replacement on bronchopulmonary dysplasia in extremely preterm infants</article-title><source>Arch Dis Child Fetal Neonatal Ed</source><year>2007</year><volume>92</volume><fpage>F94</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16905572</pub-id></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreiber</surname><given-names>MD</given-names></name><name><surname>Gin-Mestan</surname><given-names>K</given-names></name><name><surname>Marks</surname><given-names>JD</given-names></name><name><surname>Huo</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Srisuparp</surname><given-names>P</given-names></name></person-group><article-title>Inhaled nitric oxide in premature infants with the respiratory distress syndrome</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><fpage>2099</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">14645637</pub-id></element-citation></ref></ref-list></back></article>